The advantages of antibodies as therapeutics - namely their high affinity, specificity, potency, stability, manufacturability and low toxicity - are compelling. Nevertheless, there are many challenges associated with antibody discovery and development that require key technical advances to improve the ...
Nevertheless, there are still significant challenges ahead for basic and applied research relating to therapeutic antibodies. This special issue of the journal provides reviews and opinions that relate to the discovery, design and deployment of antibodies as therapeutics....
The use of monoclonal antibodies as therapeutics requires optimizing several of their key attributes. These include binding affinity and specificity, folding stability, solubility, pharmacokinetics, effector functions, and compatibility with the attachment of additional antibody domains (bispecific antibodies) ...
A new design for bispecific antibodies enables efficient production of stable molecules with good pharmacodynamic properties. Antibody-based therapeutics have shown remarkable success in the treatment of conditions such as cancer, inflammation and infectious disease. Yet the clini... S Morrison 被引量: ...
Monoclonal antibodies (mAbs) are attractive therapeutics for treating a wide range of human disorders, and bind to the antigen through their complementarity-determining regions (CDRs). Small stable proteins containing structurally retained CDRs are promising alternatives to mAbs. In this report, we pre...
Assisted Design of Antibody and Protein Therapeutics (ADAPT) is an affinity maturation platform interleaving predictions and testing that was previously validated on monoclonal antibodies (mAbs). This study expands the applicability of ADAPT to single-domain antibodies (sdAbs), a promising class of reco...
In this review, we will discuss examples of polypeptide-drug conjugates as single or combination therapies in both preclinical and clinical studies as therapeutics and molecular imaging tools. Importantly, we will critically discuss relevant examples to highlight those parameters relevant to their ...
The treatment of patients with cancer using passive vaccination with antibodies has been demonstrated to be a promising option, particularly for 'soft tumo... Z Eshhar - 《Current Opinion in Molecular Therapeutics》 被引量: 99发表: 2010年 ...
P. Evolution of the eukaryotic protein kinases as dynamic molecular switches. Philos Trans R Soc Lond B Biol Sci. 367, 2517–2528 (2012). Article CAS Google Scholar Mandell, J. W. Phosphorylation state-specific antibodies: applications in investigative and diagnostic pathology. Am J Pathol 163...
This phenomenon is also an obstacle in so-called targeted therapies that use novel agents such as kinase inhibitors as well as in non-small therapeutics such as monoclonal antibodies2. Therefore, although novel small-molecule agents are still in demand, newly designed compounds are required to ...